For the quarter ending 2025-09-30, CARM made $45,250,000 in revenue. $44,717,000 in net income. Net profit margin of 98.82%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Collaboration revenues | 45,250,000 | 0 | 3,729,000 | 3,525,000 |
| Research and development | 197,000 | 2,424,000 | 9,156,000 | 16,520,000 |
| General and administrative | 1,239,000 | 3,354,000 | 3,907,000 | 5,687,500 |
| Total operating expenses | 1,436,000 | 5,778,000 | 13,063,000 | 22,207,500 |
| Operating loss | 43,814,000 | -5,778,000 | -9,334,000 | -18,682,500 |
| Gain (loss) on sale of held for sale assets | 320,000 | -3,539,000 | - | - |
| Loss on abandonment of operating lease right-of-use asset | 0 | 927,000 | - | - |
| Interest income, net | - | - | 68,000 | 376,000 |
| Other income, net | 583,000 | 470,000 | - | - |
| Pre-tax income(loss) | 44,717,000 | -9,774,000 | -9,266,000 | - |
| Income tax expense | 0 | 0 | - | - |
| Net income(loss) | 44,717,000 | -9,774,000 | -9,266,000 | -18,306,500 |
| Comprehensive loss | - | - | - | -18,306,500 |
| Earnings per share, basic | 1.07 | -0.23 | -0.22 | -0.44 |
| Earnings per share, diluted | 1.07 | -0.23 | -0.22 | -0.44 |
| Weighted average number of shares outstanding, basic | 41,788,096 | 41,788,096 | 41,771,213 | -20,794,061,171.5 |
| Weighted average number of shares outstanding, diluted | 41,940,292 | 41,788,096 | 41,771,213 | -20,794,061,171.5 |
Carisma Therapeutics Inc. (CARM)
Carisma Therapeutics Inc. (CARM)